Xspray Pharma AB (publ)
SSE:XSPRAY.ST
44 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Xspray Pharma AB (publ) |
Symbool | XSPRAY.ST |
Munteenheid | SEK |
Prijs | 44 |
Beurswaarde | 1,375,154,000 |
Dividendpercentage | 0% |
52-weken bereik | 28.1 - 83.736 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Per Andersson Ph.D. |
Website | https://www.xspraypharma.com |
An error occurred while fetching data.
Over Xspray Pharma AB (publ)
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)